Published in Biotech Law Weekly, August 26th, 2005
"The brain and neuromodulation are widely considered to be the next frontiers for medical devices similar to the heart and cardiac rhythm management in the early '60s," commented Robert P. ("Skip") Cummins, Cyberonics' chairman of the board and CEO.
"Cyberonics is uniquely positioned, with the intellectual property, regulatory and market franchises, and proven core competencies, to rapidly become the leader in that next frontier."
"Over the next 5 years,...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Biotech Law Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.